<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5050">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02149602</url>
  </required_header>
  <id_info>
    <org_study_id>CCR 2588</org_study_id>
    <nct_id>NCT02149602</nct_id>
  </id_info>
  <brief_title>A Phase II Study of Parotid-gland Sparing IMRT in Patients With Midline Tumour of the Head and Neck</brief_title>
  <acronym>PARSPORT-II</acronym>
  <official_title>A Phase II Study of Parotid-gland Sparing Intensity-modulated Radiotherapy in Patients With Midline Tumour of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal Marsden NHS Foundation Trust</source>
  <oversight_info>
    <authority>United Kingdom: Royal Marsden Committee of Clinical Research and Local and National Research and Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase II trial designed to test the feasibility of delivering IMRT to head
      and neck cancer patients with tumours arising in the midline (oropharynx and hypopharynx),
      and to assess possible improvement in reducing the incidence of xerostomia with bilateral
      superficial lobe parotid sparing IMRT.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>The proportion of patients reporting grade 2 or more xerostomia using subjective measure on the LENTSOMA late toxicity scoring scale one year after treatment.</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute radiation toxicity</measure>
    <time_frame>0-3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late radiation toxicity</measure>
    <time_frame>3-24  months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival outcomes for entire cohort and according to HPV status where available : Local control,  Loco regional control,  Loco-regional progression-free survival (LRPFS),  Disease free survival,  Overall survival.</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">120</enrollment>
  <condition>Oropharyngeal Squamous Cell Cancer</condition>
  <condition>Hypopharyngeal Squamous Cell Cancer</condition>
  <arm_group>
    <arm_group_label>oropharyngeal and hypopharyngeal HNSCC</arm_group_label>
    <description>Intensity Modulated Radiotherapy HPV positive and HPV negative</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity modulated radiotherapy</intervention_name>
    <description>Bilateral superficial lobe parotid sparing intensity modulated radiotherapy</description>
    <arm_group_label>oropharyngeal and hypopharyngeal HNSCC</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Midline pharyngeal squamous cell cancers (excluding nasopharyngeal cancers)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically confirmed locally advanced HNSCC arising from the oropharynx or
             hypopharynx with high risk of bilateral parapharyngeal space involvement

        Exclusion Criteria:

          -  Patients &lt;18 years old or with a previous malignancy other than non-melanomatous skin
             cancer
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher M Nutting, FRCR</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Head and Neck Unit, Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 26, 2014</lastchanged_date>
  <firstreceived_date>May 26, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>involvement of bilateral parapharyngeal spaces</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Neoplasms, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
